Credit Suisse resumed coverage on Ikena Oncology with a new price target

4/26/21 8:52:04 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Credit Suisse resumed coverage of Ikena Oncology with a rating of Outperform and set a new price target of $30.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IKNA

Date	Price Target	Rating	Analyst
5/29/2024	$8.00 → $2.00	Outperform → Neutral	Wedbush
9/22/2023	$11.00	Outperform	Wedbush
5/4/2023	$18.00	Buy	H.C. Wainwright
12/23/2021	$25.00	Buy	HC Wainwright & Co.
8/13/2021	$30.00 → $27.00	Outperform	Credit Suisse